THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER

Prostate cancer initially responds to androgen-deprivation therapy, but most patients eventually develop a castration-resistant form of disease. Enzalutamid is the superselective inhibitor of the androgen receptor (AR), which blocks several stages of the AR signal path. The drug showed significant e...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV
Aineistotyyppi: Artigo
Kieli:Russo
Julkaistu: Remedium Group LLC 2017-06-01
Sarja:Медицинский совет
Aiheet:
metastatic cancer
enzalutamide
abiraterone acetate
castration resistance
Linkit:https://www.med-sovet.pro/jour/article/view/1894
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia